medigraphic.com
ISSN 1995-9494 (Electronic)
Revista del Hospital Clínico Quirúrgico "Arnaldo Milián Castro"

2014, Number 4

<< Back Next >>

Acta Med Cent 2014; 8 (4)

Results of the use of Heberprot-P®

González BC, Pérez MLM, Peraltas PG

Language: Spanish
References: 20
Page: 16-23
PDF size: 179.77 Kb.


ABSTRACT

Introduction: diabetes mellitus is one of the most important in the twenty-first century by the high morbidity and mortality associated with complications health problems. It is a disease of major importance in terms of public health throughout the world for being one of the most common non-communicable and that has increased dramatically in the past 25 years. One of the most frequent complications of diabetic foot ulcer associated with neurological, vascular and infectious disorders.
Objective: to describe the results of Heberprot-P® in diabetic foot ulcers in patients treated in the Department of Angiology and Vascular Surgery.
Methods: an observational, descriptive, cross-sectional study was conducted among patients at "Arnaldo Milian Castro" Surgical Clinic Hospital of the City of Santa Clara, Villa Clara Province, in the period from January to December 2012.
Results: predominated male patients from 60 to 69 years and grades 2, 3 and 4 of the Wagner and the neuroinfectious criteria of Mc Cook ranking. Most of the patients had a location of your ulcer on the right lower limb and fingers. The effectiveness of treatment with Heberprot-P® was significantly high. The comparison between treated and untreated with Heberprot-P® showed that the number of major amputations of the first was much smaller.
Conclusions: Heberprot-P® therapy was effective and significantly reduced the number of major amputations in this center.


REFERENCES

  1. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2012 Jan [Internet];35 Suppl 1[citado 2 Sept 2014]:[aprox. 7 p.]. Disponible en: http://care.diabetesjournals.org/content/35/Supplement_1/S64.extract

  2. Brise JB, Polonsky KS, Burant CF. Type 2 diabetes mellitus. En: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS. Willians Textboook of Endocrinology. 10th ed. Philadelphia: Saunders; 2003. p. 1427-84.

  3. Fernández-Montequín JI, Betancourt BY, Leyva-Gonzalez G, Mola EL, Galán-Naranjo K, Ramírez-Navas M, et al. Intralesional administration of epidermal growth factorbased formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to complete wound closure. Int Wound J 2009;6(1):67-72.

  4. Zaulyanov L, Kirsner RS. A review of a bi-layered living cell treatment (Apligraf) in the treatment of venous leg ulcers and diabetic foot ulcers. Clin Interv Aging. 2007;2(1):93-8.

  5. Llanes BJA, Fernández MJI, Seuc HA, Álvarez DTH, Chirino CN, Valdés PC, et al. Utilidad del Michigan Neuropathy Program para identificar clínica de neuropatía diabética y evaluar su severidad. Angiología [Internet]. 2008 Ene-Dic [citado 9 May 2011];9(1):[aprox. 3 p.]. Disponible en: http://bvs.sld.cu/revistas/ang/vol9_1_08/ang16104.htm

  6. Rodríguez GD. Caracterización de pacientes con pie diabético del Hospital Militar de Holguín. Corr Med Cient Holg [Internet]. 2012 Ene-Mar [citado 5 Oct 2013];16(1): [aprox. 3 p.]. Disponible en: www.revcocmed.sld.cu/index.php/cocmed/article/view/80

  7. Conesa González AJ, Diaz Diaz O, Conesa del Rio JR, Domínguez Alonso JE. Mortalidad por Diabetes mellitus y sus complicaciones, Ciudad de la Habana, 1990- 2002. Rev Cub Endocrinol. 2010;21(1):35-50.

  8. Fernández-Montequín JI, Infante-Cristiá E, Valenzuela-Silva C, Franco-Pérez N, Savigne-Gutiérrez W, Artaza-Sanz H, et al. Intralesional injections of Citoprot-P® (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. Int Wound J. 2007;4(4):333-43.

  9. Bolívar Y, Mena M, Brito S, Fernández M, Chacín B, Lares M, et al. Evaluación y seguimiento de los pacientes de la unidad de Pie Diabético del departamento de endocrinología del hospital militar Dr. Carlos Arvelo y su comparación con estándares internacionales. Rev Venez Endocrinol Metab [Internet]. 2010 Jun [citado 5 Oct 2013];8(2):[aprox. 4 p.]. Disponible en: http://www.scielo.org.ve/scielo.php?script=sci_arttext&pid=S1690- 31102010000200005&lng=pt&nrm=iso

  10. Monteiro-Soares M, Boyko J, Ribeiro J, Ribeiro I, Dinis-Ribeiro M. Risk stratification systems for diabetic foot ulcers: a systematic review. Diabetología. 2011 May;54(5):1190-9. doi: 10.1007/s00125-010-2030-3. Epub 2011 Jan 20.

  11. Lipsky BA. Evidence-based antibiotic therapy of diabetic foot infections. FEMS Immunol Med Microbiol 1999;26:267-76.

  12. Rivero F. Experiencias del Programa de atención integral a pacientes con pie diabético en el estado Zulia, Venezuela. Biotecnol Apl La Habana [Internet]. 2010 Abr.-Jun [citado 5 Oct 2013];27(2):[aprox. 4 p.]. Disponible en: http://scielo.sld.cu/scielo.php?pid=S1027-28522010000200004&script=sci_arttext

  13. Rivero F. Programa de prevención del pie diabético. Iniciativa local para un problema global. Rev Cubana Angiol Cir Vasc [Internet]. 2006 [citado 12 Ago 2010];7(1):[aprox. 4 p.]. Disponible en: http://bvs.sld.cu/revistas/ang/vol7_1_06/ ang04106.htm

  14. Gaffaro de Valera L. Programa de Atención Integral a pacientes con pie diabético. Caracas, Venezuela: Taller inicial; 2008.

  15. Gospodarowicz D. Epidermal and nerve growth factor in mammalian development. Ann Rev Physiol [Internet]. 1981 Mar [citado 12 Ago 2010];43:251-63. Disponible en: www.annualreviews.org/doi/abs/10.1146/annurev.ph.43.030181.001343

  16. Gimeno Orna JA, Boned Juliani B, Lou Arnal LM, Castro Alonso FJ. Factores relacionados con el control glucémico de pacientes con diabetes tipo 2. An Med Interna (Madrid). 2003;20:122-26.

  17. Wraight PR, Lawrence SM, Campbell DA, Colman PG. Creation of a multidisciplinary, evidence based, clinical guideline for the assessment, investigation and management of acute diabetes related foot complications. Diabet Med. 2005 Feb;22(2):127-36.

  18. Bakker K. Schaper NC. The development of global consensus guidelines on the management and prevention of the diabetic foot 2011. Diabetes Metab Res Rev. 2012 Feb;28 Suppl 1:116-8. doi: 10.1002/dmrr.2254.

  19. Bakker KJ. Practical guidelines on the management and prevention of the diabetic foot 2011. Diabetes Metab Res Rev. 2012;28(Suppl 1):225–31.

  20. Vamos EP, Bottle A, Majeed A, Millett C. Trends in lower extremity amputations in people with and without diabetes in England, 1996-2005. Diabetes Res Clin Pract. 2010 Feb;87(2):275-82. doi: 10.1016/j.diabres.2009.11.016.




2020     |     www.medigraphic.com